OREX

Orexigen Therapeutics, Inc. Press Releases

$6.33
*  
0.04
0.64%
Get OREX Alerts
*Delayed - data as of Dec. 19, 2014  -  Find a broker to begin trading OREX now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Orexigen's Mysimba™ (naltrexone HCl / bupropion HCl prolonged release) Receives Positive CHMP Opinion Recommending Approval for Weight Management in the European Union
12/19/2014 7:19:00 AM - PR Newswire
▲0.16 % Price Change since this news event. The Volume Ratio is 3.02.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Orexigen Therapeutics to Present at the Piper Jaffray Healthcare Conference
11/26/2014 8:30:00 AM - PR Newswire


Orexigen Announces Allowance of New U.S. Patent for Contrave® (naltrexone HCl / bupropion HCl extended release)
11/21/2014 8:00:00 AM - PR Newswire


Orexigen Therapeutics Reports Results for the Third Quarter Ended September 30, 2014
11/10/2014 7:00:00 AM - PR Newswire
▲64.42 % Price Change since this news event. The Volume Ratio is 9.08.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Orexigen Therapeutics to Present at the Credit Suisse Healthcare Conference
11/6/2014 4:30:00 PM - PR Newswire
▲62.31 % Price Change since this news event. The Volume Ratio is 2.29.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Orexigen Therapeutics to Host Third Quarter 2014 Financial Results Conference Call and Webcast
11/4/2014 4:15:00 PM - PR Newswire
▲56.30 % Price Change since this news event. The Volume Ratio is 0.89.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Orexigen Announces Contrave® (naltrexone HCI and bupropion HCI extended release) Data Presentations at the ObesityWeek Meeting in Boston
10/31/2014 8:30:00 AM - PR Newswire
▲53.27 % Price Change since this news event. The Volume Ratio is 0.75.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Orexigen Therapeutics Analyst Coverage Initiated with Price Target by BrokerBank Securities, Inc.
10/23/2014 7:00:00 AM - PR Newswire
▲46.53 % Price Change since this news event. The Volume Ratio is 0.63.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Takeda and Orexigen Announce Availability of CONTRAVE® (naltrexone HCI and bupropion HCI) Extended-Release Tablets for Chronic Weight Management in Obese Adults
10/20/2014 8:00:00 AM - PR Newswire
▲56.30 % Price Change since this news event. The Volume Ratio is 0.92.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Milestone Payments Earned by Orexigen Total $100 Million as Contrave® (naltrexone HCI and bupropion HCI extended release) is Shipped to Wholesalers in Preparation for Commercial Launch
10/15/2014 8:30:00 AM - PR Newswire
▲86.73 % Price Change since this news event. The Volume Ratio is 1.53.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day